Medscape April 9, 2025
SAN DIEGO — An adjunctive, first-in-class investigational prescription digital therapeutic significantly reduced monthly migraine days (MMDs) in patients with episodic migraine (EM) compared with sham results of a large study showed.
CT-132 (Click Therapeutics) is a mobile smartphone app that “targets top-down pain processing and central sensitization” using behavioral approaches and includes an eDiary tracker and short daily lessons/exercises with a decision-support tool, the investigators reported.
In the phase 3 ReMMi-D trial, which included more than 500 adult patients with EM, those randomly assigned to receive CT-132 for 4 weeks showed significantly reduced MMDs compared with those who received a sham digital therapeutic — meeting its primary endpoint. They also had significantly reduced disability and improved quality-of-life outcomes, along with...
Today's Sponsors
Today's Sponsor